Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gaylis

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Advances in Therapy|April 28, 2025
Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature ReviewPiotr Wiland, Charlotte Both, Norman B Gaylis, et al.
The Journal of Rheumatology|March 3, 2010
Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trialPhilip J Mease, Stanley Cohen, Norman B Gaylis, et al.
BMC Musculoskeletal Disorders|June 3, 2014
Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA studyCharles H Pritchard, Maria W Greenwald, Joel M Kremer, et al.
Rheumatology (Oxford, England)|September 20, 2011
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysisPaul Emery, Philip J Mease, Andrea Rubbert-Roth, et al.
The Lancet. Rheumatology|January 26, 2024
Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot studyMark C Genovese, Norman B Gaylis, David Sikes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2022
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 SyndromeNorman B Gaylis, Angela Ritter, Scott A Kelly, et al.
The Journal of Rheumatology|September 3, 2011
Magnetic resonance imaging in rheumatoid arthritis clinical trials: emerging patterns based on recent experienceCharles G Peterfy, Peter Countryman, Annarita Gabriele, et al.
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality|September 1, 2010
Preprinted standardized orders promote venous thromboembolism prophylaxis compared with traditional handwritten orders: an endorsement of standardized evidence-based practiceFranklin D Gaylis, Sothary J Van, Michael A Daneshvar, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 29, 2020
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA StudyPiotr Wiland, Sławomir Jeka, Eva Dokoupilová, et al.
Nature Medicine|December 22, 2025
Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trialJohn R P Tesser, Angela R Crowley, Emily Jane Box, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Advances in Therapy|April 28, 2025
Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature ReviewPiotr Wiland, Charlotte Both, Norman B Gaylis, et al.
The Journal of Rheumatology|March 3, 2010
Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trialPhilip J Mease, Stanley Cohen, Norman B Gaylis, et al.
BMC Musculoskeletal Disorders|June 3, 2014
Safety of infusing rituximab at a more rapid rate in patients with rheumatoid arthritis: results from the RATE-RA studyCharles H Pritchard, Maria W Greenwald, Joel M Kremer, et al.
Rheumatology (Oxford, England)|September 20, 2011
Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysisPaul Emery, Philip J Mease, Andrea Rubbert-Roth, et al.
The Lancet. Rheumatology|January 26, 2024
Safety and efficacy of neurostimulation with a miniaturised vagus nerve stimulation device in patients with multidrug-refractory rheumatoid arthritis: a two-stage multicentre, randomised pilot studyMark C Genovese, Norman B Gaylis, David Sikes, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2022
Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 SyndromeNorman B Gaylis, Angela Ritter, Scott A Kelly, et al.
The Journal of Rheumatology|September 3, 2011
Magnetic resonance imaging in rheumatoid arthritis clinical trials: emerging patterns based on recent experienceCharles G Peterfy, Peter Countryman, Annarita Gabriele, et al.
American Journal of Medical Quality : the Official Journal of the American College of Medical Quality|September 1, 2010
Preprinted standardized orders promote venous thromboembolism prophylaxis compared with traditional handwritten orders: an endorsement of standardized evidence-based practiceFranklin D Gaylis, Sothary J Van, Michael A Daneshvar, et al.
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 29, 2020
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA StudyPiotr Wiland, Sławomir Jeka, Eva Dokoupilová, et al.
Nature Medicine|December 22, 2025
Vagus nerve-mediated neuroimmune modulation for rheumatoid arthritis: a pivotal randomized controlled trialJohn R P Tesser, Angela R Crowley, Emily Jane Box, et al.
Pageof 3